PROMOMED is growing 6 times faster than the market: revenue growth was +78% in 9 months of 2025

November 18, 2025, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly –PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the Group's operating results for the first 9 months of 2025.

In Q1 2025, PROMOMED Group demonstrated the highest growth dynamics of financial indicators among issuers of shares of the Moscow Exchange listing level 1-2[1] and continues to successfully implement the Company's shareholder value growth strategy in the reporting period.:

• The Group's revenue for 9 months of 2025 increased by 78%[2] and reached RUB 19 billion. PROMMED's revenue growth is 6 times higher than the pharmaceutical market's growth rate in value terms, which was 12.6% according to IQVIA (17% in 9 months of 2024).
• Revenue growth was driven by new drug launches in the Key Portfolio (+44%) and increased sales and drug launches in the Core Portfolio (+34%).
• The share of Endocrinological and Oncological portfolios in revenue for 9 months of 2025 increased by 22 percentage points and amounted to 75% (53% for 9 months of 2024).
• The company confirms its financial performance forecast for 2025: revenue growth of 75% with an EBITDA margin of 40%.

The Group's revenue growth rate is 6 times higher than the pharmaceutical market growth rate

The share of revenue from Endo and Onco drugs increased by 22 percentage points to 75%

Alexander Efremov, General Director of PJSC PROMOMED:

"PROMOMED strengthens the technological leadership in Russian biopharmaceuticals.
In the third quarter of 2025, we launched an innovative preservative-free drug, Velgia® ECO, to combat obesity, and the effective over-the-counter analgesics Reitbufen® and Migrenium®. Amberwin® Pulmo is a new and first-in-class drug for the treatment of lung inflammation in a wide range of diseases. In October, the registration certificate of the first Russian semaglutide in tablets, Semaltara®, was received ahead of schedule, combining well-known efficacy and comfortable use.

We have set an ambitious goal to achieve revenue growth of 75% in 2025. The interim results for 9 months allow us to confirm the forecast with confidence and prove the effectiveness of the Company's strategy and operating model. An integrated full–cycle production model combined with successful commercialization is a solid foundation for shareholder value growth."

ENDOCRINOLOGY

In the Endocrinology market segment, revenue for 9 months of 2025 increased by 157% compared to 9 months of 2024 and amounted to 8 billion rubles, primarily due to the successful sales of new products – Velgia®, Velgia® ECO and Tirzetta®. The growth of the relevant market of drugs for diabetes and obesity, including 9 INN medicines, amounted to 99% in the reporting period, to 30.4 billion rubles.

• Tirzetta® is an innovative drug for the treatment of obesity and type II diabetes mellitus, the first and only direct competitor of the American Mounjaro on the Russian market.
• Velgia® is an innovative new generation drug for the treatment of obesity. In 9 months of 2025, the drug entered the TOP 10[3] in terms of growth rates among all medicines in the retail segment, confirming its status as one of the most in-demand modern products. Velgia® ECO is a drug free of phenol, benzyl alcohol and other preservatives, which opens up application possibilities for patients with hypersensitivity and liver and kidney diseases.

ONCOLOGY
In the Oncology segment, revenue for 9 months of 2025 increased by 132% compared to 9 months of 2024 and amounted to 5.9 billion rubles. The relevant market, which includes 29 innes, temporarily decreased by 12% to 21.8 billion rubles in the reporting period due to the calendarization of public procurement.

• Apalutamide-Promomed is the first Russian second—generation androgen receptor inhibitor for the treatment of prostate cancer. Its cost is almost 40% lower than its imported counterparts.
• Cabozantinib-PROMOMED and other drugs from the basic Cancer portfolio — continued to increase sales.

Other DRUGS: GENERAL THERAPY, ANTIVIRAL, NEUROLOGY, IMMUNOLOGY, ANTIBIOTICS, VETERINARY MEDICINE, AND OTHERS
In the Other drugs segment, revenue for 9 months of 2025 increased by 1% compared to 9 months of 2024 and amounted to 5 billion rubles. The growth of the relevant market out of 161 INN was 5% to 165.6 billion rubles. In the reporting period, 4 innovative drugs were launched on the market, the revenue from which is expectedstarting from the 4th quarter of 2025.

• Amberwin® Pulmo is a first—in-class drug with a unique mechanism of action aimed at repairing lung tissue, treating pneumonia, and preventing complications from respiratory tract infections. According to the Rospotrebnadzor report for 2024, the incidence of pneumonia in Russia was 867 cases per 100,000 population, which means that more than 1 million adult patients suffer from community-acquired pneumonia every year.
• Migrenium® Neo is a new drug based on ibuprofen, the analgesic effect of which is enhanced by caffeine. This combination of components provides a rapid and pronounced effect on headaches, migraines and dysmenorrhea. In Russia, migraines affect about 20.8% of the adult population, which is almost 30 million people. This is one of the highest rates in the world.
• Reitbufen® is an innovative new generation analgesic with the active ingredient dexibuprofen, characterized by high efficacy and a favorable safety profile. Dexibuprofen inhibits inflammatory factors more effectively, due to which the result is achieved faster and more pronounced.

Both analgesic drugs belong to the over-the-counter segment of the market, which opens up qualitatively new opportunities for their promotion and commercialization. The analgesic market reached 28.1 billion rubles in 9 months of 2025, showing an increase of 11% year-on-year.[4]

• Teduglutide is an orphan drug for the treatment of short bowel syndrome, a rare and severe disease. The drug reduces dependence on parenteral nutrition to the point of complete rejection, strengthens the intestinal barrier function, reduces inflammation and significantly improves the quality of life: fewer hours on infusions, more mobility and freedom in everyday life. The pronounced anti-inflammatory and reparative effect makes the drug a promising candidate for preoperative preparation and recovery after treatment of traumatic lesions. The volume of the relevant market in 2024 amounted to 4.1 billion rubles.
• The development has been completed and registration certificates for drugs for the treatment of hepatitis C and orphan diseases, in particular spinal muscular atrophy (SMA), have been obtained.

In the reporting period, the Group completed the registration process for two innovative veterinary drugs at once. The volume of the relevant market for medicines for small pets increased by 20% in 9 months of 2025 and amounted to 1.5 billion rubles. By 2032, the Group sets a strategic goal to occupy a market share of 25-50% in veterinary pharmaceuticals.

• Amklav® VET — launched on the market in Q3 2025, a first-choice combination drug with increased efficacy in the treatment of skin diseases, urinary tract infections, bacterial enteritis and respiratory bacterial infections in animals.

OPERATIONAL INDICATORS

Indicators for the reporting period	9m2025	9m2024
Number of new patents, pcs.	18	14
Number of new registration certificates, pcs.	21	34
Indicators as of the reporting date	30.09.25	30.09.24
Number of patents, pcs.	93	73
Number of drugs in the portfolio, pcs.	364	339
Number of trademarks, pcs.	610	503
Number of employees	2 713	2 181
Number of employees in R&D	541	446

About the Company

PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market. In 2025, PROMOMED celebrates the 20th anniversary of the Company's founding.

The Company's structure includes its own uniqueIt is a world-class R&D center and a high–tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 350 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.
Contacts

For investors	For the media
ir@promomed.pro	pr@promomed.pro

Statement of limitation of liability

This message and the information contained therein are not:

• an offer to purchase any securities,
• an invitation to make offers for the purchase of any securities,
• as part of such offers or invitations,
• securities advertising in the Russian Federation or other jurisdictions,
• an offer to purchase medicines,
• advertising of medicines,
• by encouraging or recommending transactions,
• it is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page.https://e-disclosure.ru/portal/company.aspx?id=38533.

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the OSU Group operateeconomic activity; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.

---

[1] Source: Cbonds

[2] According to management reporting data

[3] According to the DSM

[4] According to Alpha R&M